Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430050 · ClinicalTrials.gov registry record · Early Phase 1
Progesterone for Cannabis Withdrawal
A Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03430050 is a Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal that has completed, run by Medical University of South Carolina. The registered enrollment target is 8 participants, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03430050, a Early Phase 1 study of Cannabis Use Disorder and Cannabis Withdrawal, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have begun to examine their utility as possible pharmacotherapeutic agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine and nicotine users, but has not yet been tested for cannabis. Gender differences in cannabis withdrawal, which is associated with relapse, are pronounced and several studies report more severe and impairing withdrawal symptoms in women compared to men. Developing pharmacological interventions for cannabis withdrawal remains an important priority given the significant cognitive, psychiatric, and physical consequences of heavy cannabis use.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Progesterone
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2018-04-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430050
The ClinicalTrials.gov registry entry for NCT03430050 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (93% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03430050 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT03430050 about?
NCT03430050 is a clinical study titled "Progesterone for Cannabis Withdrawal". Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have be...
What is the current status of trial NCT03430050?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2017-10-16. Estimated completion is 2018-04-04.
What conditions does trial NCT03430050 study?
This clinical trial studies the following conditions: Cannabis Use Disorder, Cannabis Withdrawal.
What interventions are being tested in trial NCT03430050?
The interventions under investigation include: Placebo (DRUG), Progesterone (DRUG).
Who is sponsoring clinical trial NCT03430050?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03430050 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
Cannabinoids and Biological Reactivity to Stress
RECRUITING · Early Phase 1
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
RECRUITING · NA
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
Psilocybin-assisted Treatment for Cannabis Use Disorder
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.